CIMZIA PACKAGE INSERT PDF

CIMZIA is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis; CIMZIA is indicated for the treatment of . drug interactions. o Cimzia is indicated for reducing signs and symptoms of Crohn’s disease and modifying anti-rheumatic drug (DMARD). 3. Cimzia [package insert]. Smyrna. Medscape – Rheumatoid arthritis and Crohn disease dosing for Cimzia ( certolizumab pegol), frequency-based adverse effects, comprehensive interactions.

Author: Daizuru Mishakar
Country: Mali
Language: English (Spanish)
Genre: Finance
Published (Last): 15 July 2011
Pages: 219
PDF File Size: 16.8 Mb
ePub File Size: 8.45 Mb
ISBN: 481-4-51500-803-2
Downloads: 61324
Price: Free* [*Free Regsitration Required]
Uploader: Mikalrajas

These cases have had a very aggressive disease course and have been fatal.

Cimzia | European Medicines Agency

Reactions have included angioedema, anaphylactoid reaction, serum sickness, and urticaria. Patients treated with CIMZIA are at increased risk for developing serious infections that may lead to hospitalization or death. In patients with active rheumatoid arthritis who had never received DMARDs, treatment with Cimzia led to sustained remission no detectable disease activity after 52 weeks of treatment.

Similar results were seen in a study with patients who had not adequately responded to other medicines such as methotrexate. An overview of Cimzia and why it is authorised in the EU Cimzia is a medicine that is used in adults to treat the following diseases: Changes since initial authorisation of medicine List item.

Digital Security

Carefully consider the risks and benefits of treatment with CIMZIA prior to initiating therapy in the following patients: As for all medicines, data on the use of Cimzia are continuously monitored. Active tuberculosis TBincluding reactivation of latent TB.

By blocking TNF-alpha, certolizumab pegol reduces inflammation and other symptoms of the diseases. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. In clinical trials, more cases of malignancies were observed among CIMZIA-treated patients compared to control patients. Cimzia is mostly used for conditions that are severe, moderately severe or getting worse, or when patients cannot use other treatments. Almost all of these patients had received treatment with azathioprine or 6-mercaptopurine concomitantly with a TNF blocker at or prior to diagnosis.

  CASSINUS AND PETER PDF

Dosing Information

Important Safety Information contraindications CIMZIA is contraindicated in patients with a history of hypersensitivity reaction to certolizumab pegol or to any of the excipients. Effect of certolizumab pegol pckage multiple facets of psoriatic arthritis as reported by patients: How useful was this page? Exercise caution and monitor carefully. All other trademarks and registered trademarks are the property of their respective holders. Rheumatoid arthritis Cimzia, in combination with methotrexate MTXis indicated for: A new generation of high-affinity humanized PEGylated Fab’ fragment anti-tumor necrosis factor-alpha monoclonal cimzzia.

Patients on Cimzia mg every two weeks led to Click to open Full Prescribing Information. Cimzia is indicated for the treatment of adult patients with severe active axial spondyloarthritis, comprising:.

Also, X-rays showed that joint damage worsened to a lesser extent in patients who received Cimzia. Nine main studies involving over 3, patients have found Cimzia effective for reducing symptoms of inflammatory conditions.

The inflammatory bowel disease questionnaire: Efficacy and safety of certolizumab pegol in a broad population of packzge with active rheumatoid arthritis: For active rheumatoid arthritis that had not improved adequately with disease-modifying antirheumatic drug DMARD treatment, two main studies found Cimzia effective when used with methotrexate when compared with placebo dummy treatment.

Expand all Collapse all. Consider empiric anti-fungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness. Malignancies, some fatal, have been reported among children, adolescents, innsert young adults being treated with TNF blockers.

Cimzia can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Please see full Prescribing Information. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with CIMZIA, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.

  644-906 IMTXR PDF

We’re strengthening digital security to protect you.

The studies included adults with active rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis and moderate to severe plaque psoriasis:. CIMZIA is contraindicated in patients with a history of hypersensitivity reaction to certolizumab pegol or to any of the excipients.

The most common side effects with Cimzia affecting up to 1 in 10 people are bacterial infections including abscesses cavities containing pusviral infections including herpes, papillomavirus and influenza packaye, eosinophilic disorders disorders of eosinophils, a type of white blood cellleucopenia low white blood cell countsnausea feeling sickheadaches including migrainesensory abnormalities such as numbness, tingling and burning sensationhigh blood pressure, hepatitis liver inflammation including increased levels of liver enzymes, rash, fever, pain, weakness, itching and reactions at the injection site.

N Engl J Med.

Anatomical therapeutic chemical ATC code. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Psoriatic arthritis Cimzia, in combination with MTX, is indicated for the treatment of active psoriatic arthritis in adults when the response to previous DMARD therapy has been inadequate.

Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection.

In the treatment of moderate to severe plaque psoriasis, Cimzia was compared with placebo in two main studies.